This content is provided for educational purposes only. It does not constitute medical advice, diagnosis, or treatment. Results vary by individual. Always consult a licensed healthcare professional before starting any diet, fitness, or medication programme.

Liraglutide (Saxenda) is an FDA‑approved GLP‑1 receptor agonist used for chronic weight management in adults and adolescents with obesity. It helps reduce appetite and support weight loss when combined with diet and exercise, but it carries gastrointestinal side effects and a boxed warning for thyroid tumors.

🧬 What is Liraglutide (Saxenda)?

• Saxenda is a once‑daily injectable medication containing liraglutide.
• Approved for adults with BMI ≥ 30 or BMI ≥ 27 with weight‑related conditions (e.g., hypertension, diabetes, high cholesterol).
• Also approved for adolescents aged 12–17 years with obesity and body weight ≥ 60 kg.
• Works by reducing appetite and slowing gastric emptying, helping patients feel full longer.

✅ Advantages

• Clinically proven weight loss: Trials show average reductions of 4–6 kg compared to placebo.
• Improved glycemic control: Beneficial for patients with type 2 diabetes.
• FDA approval: Recognized as safe and effective for long‑term weight management.
• Daily dosing flexibility: Adjustable doses (0.6 mg → 3 mg) allow gradual titration.

⚠️ Disadvantages

• Boxed warning: Risk of thyroid C‑cell tumors; contraindicated in patients with family history of medullary thyroid carcinoma or MEN2.
• Common side effects: Nausea, vomiting, diarrhea, constipation, headache, injection site reactions.
• Serious risks: Rare cases of pancreatitis, gallbladder disease, and suicidal ideation.
• Cost: High monthly expense; insurance coverage varies.
• Lifestyle requirement: Must be combined with diet and exercise for effectiveness.

📊 Comparison Table